Skip to main content
. 2020 Jan 9;9(1):1703449. doi: 10.1080/2162402X.2019.1703449

Table 2.

Contemporary clinical studies assessing the therapeutic and immunological characteristics of cyclophosphamide.

Indication(s) Phase Status Notes Ref.
B cell lymphoma II Recruiting Combined with pembrolizumab and DPX-survivax NCT03349450
Breast cancer I Withdrawn Combined with doxorubicin and glembatumumab vedotin NCT03473691
I/II Recruiting Combined with SV-BR-GM, pembrolizumab and interferon inoculation NCT03328026
II Recruiting Combined with doxorubicin, nivolumab and ipilimumab NCT03409198
Not yet recruiting Combined with multimodal chemotherapy, pertuzumab, atezolizumab, trastuzumab emtansine and surgical resection NCT03894007
Recruiting Combined with epirubicin, nab-paclitaxel and pembrolizumab NCT03289819
Recruiting Combined with multimodal chemotherapy and pembrolizumab NCT03515798
III Recruiting Combined with multimodal chemotherapy and atezolizumab NCT03197935
NA Recruiting Combined with doxorubicin and alpha lipoic acid NCT03908528
Gastroesophageal cancer I/II Recruiting Combined with pembrolizumab and IRX-2 NCT03918499
Glioma I Recruiting Combined with fludarabine, temozolomide, TTRNA-DC vaccine with GM-CSF, TTRNA-xALT, autologous HSC and Td vaccine NCT03396575
Withdrawn Combined with fludarabine, GINAKIT cells NCT02439788
I/II Recruiting Combined with surgical resection and lysate-loaded dendritic cell vaccine NCT03879512
II Recruiting Combined with multimodal chemotherapy, ASCT, EBRT, sargrasmostim, dinutuximab and aldesleukin NCT03786783
Hematological malignancies I Recruiting Combined with multimodal chemotherapy, total body irradiation and cord blood stem cells NCT03885947
Not yet recruiting Combined with fludarabine and CAR-aNKT cells NCT03774654
I/II Recruiting Combined with fludarabine, ALLO-501 and ALLO-647 NCT03939026
Withdrawn Combined with GM-CSF and TAPA-pulsed DC vaccine NCT02223312
Active, not recruiting Combined with GM-CSF and TAPA-pulsed DC vaccine NCT02709993
II Recruiting Combined with fludarabine and axicabtagene ciloleucel NCT03761056
Recruiting Combined with multimodal chemotherapy, nivolumab and rituximab NCT03749018
n.s Recruiting Combined with cord blood transplantation NCT03802773
Leukemia I Recruiting NCT03241940
Recruiting Combined with fludarabine phosphate and CD19/CD22 CAR-T cell therapy NCT03233854
Not yet recruiting Combined with fludarabine, CD19 CAR-T cells and PD-1 KO engineered T cells NCT03298828
Recruiting Combined with tacrolimus, allogeneic HSC transplantation, filgrastim and total marrow irradiation NCT03467386
Recruiting Combined with fludarabine and omnlmmune NCT03790072
Recruiting Combined with leukapheresis, fludarabine and huJCAR014 NCT03103971
Recruiting Combined with fludarabine and anti-CD19/CD22 CAR-T cells NCT03919526
I/II Recruiting Combined with fludarabine and KTE-X19 NCT03624036
III Recruiting Combined with multimodal chemotherapy, TBRT, G-CSF and peripheral blood transplant NCT03480360
NA Recruiting Combined with multimodal chemotherapy, thymoglobuline, cyclosporine, lymphocyte injection of prophylactic donor and transfusion graft of peripheral stem cells NCT03035422
Liver cancer I Recruiting Combined with nivolumab and IRX-2 NCT03655002
Active, not recruiting Combined with fludarabine and GAP-T cells NCT02932956
I/II Recruiting Combined with IMA970A and CV8102 NCT03203005
Recruiting Combined with fludarabine and MUC-1 CAR-T cells NCT03633773
II/III Recruiting Combined with iNKT cells and human recombinant IL-2 NCT04011033
Lung cancer I Recruiting Combined with radiation, G-CSF and PBMCs NCT02579005
Not yet recruiting Combined with fludarabine and PD-L1 CAR-T cells NCT03330834
Melanoma I Recruiting Combined with fludarabine, IL-2, nivolumab and adoptive transfer of autologous TILs NCT03475134
Recruiting Combined with fludarabine, autologous TILs, aldesleukin, nivolumab and ipilimumab NCT03526185
Myeloid malignancies II Not yet recruiting Combined with multimodal chemotherapy cyclosporine, tacrolimus and HSC transplantation NCT03270748
Myeloma I Recruiting Combined with fludarabine and SLAMF7 CAR-T therapy NCT03710421
Recruiting Combined with fludarabine, gamma secretase inhibitor LY3039478, BCMA specific CAR-T cells NCT03502577
Recruiting Combined with fludarabine, BCMA CART and huCAR-T19, NCT03549442
Recruiting Combined with fludarabine and CAR-BCMA T cells NCT03716856
NA Recruiting Combined with fludarabine and CAR-BCMA T cells NCT03380039
Osteosarcoma II Recruiting Combined with fludarabine, fludarabine phosphate, aldesleukin and TILs NCT03449108
Ovarian cancer I Recruiting Combined with decitabine, aldesleukin, genetically engineered NY-ESO 1 specific T lymphocytes NCT03017131
Recruiting Combined with fludarabine and anti-meso CAR-T cells NCT03799913
II Withdrawn Combined with anti-CSF1 mAb PD-0360324 NCT02948101
Pancreatic cancer I Recruiting Combined with GVAX, pembrolizumab and IMC-CS4 NCT03153410
Prostate cancer I Recruiting Combined with fludarabine, fludarabine phosphate and autologous anti-PSCA-CAR-T-cells NCT03873805
Sarcoma II Withdrawn Combined with pembrolizumab, GSK3377794 and fludarabine NCT03697824
Solid and hematological malignancies I/II Recruiting Combined with CAR-T cell therapy NCT03638206
Solid malignancies I Withdrawn Combined with GM-CSF and TAPA-pulsed DC vaccine NCT02705703
Recruiting Combined with RT, aspirin, nivolumab and ipilimumab NCT03728179
I/II Recruiting Combined with fludarabine and PD-1 expressing mesoCAR-T cells NCT03615313
Active, not recruiting Combined with imiquimod topical cream and TAPA-pulsed DC vaccine NCT02224599
II Recruiting Combined with pembrolizumab and DPX-survivax NCT03836352

ALLO, allogeneic; ASCT, autologous hematopoietic stem cell transplantation; CAR-aNKT cells, CAR allogeneic natural killer T cells; CAR, chimeric antigen receptor; DC, dendritic cell; CSF-1, colony stimulating factor 1; EBRT, external beam radiation therapy; GAP, glypican 3; GINAKIT cells, GD2-specific CAR- and interleukin 15- expressing autologous NKT cells; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSC, hematopoietic stem cell; IL, interleukin; mAb, monoclonal antibody; Meso-CAR-T cells, mesothelin-redirected chimeric antigen receptor T cell; iNKT cells, invariant NKT cells; KO, knock-out; NA, not applicable; NS, not specified; PBMC, peripheral blood mononuclear cell; PSC, pluripotent stem cells; RT, radiotherapy; TAPA, tumor-associated peptide antigen; TBRT, total body RT; TD, Tetanus-Diphtheria; TIL, tumor-infiltrating lymphocyte; TTRNA, total tumor RNA; xALT, autologous lymphocyte transfer.